1601 TRAPELO ROAD, WALTHAM, MA
Invivyd, Inc. Elects New Directors at Annual Meeting of Stockholders
Reports First Quarter 2026 Financial Results and Recent Business Highlights
REVOLUTION Program & Measles April 9, 2026
Annual Report to Security Holders
Investor Presentation
Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Free Writing Prospectus